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Abstract
Introduction: Validity of biomarkers may be affected if studies do not include certain features in their design. We
evaluated whether translational research studies of potential biomarkers incorporated design features important for
valid clinical associations.
Methods: We searched 10 journals for translational studies in six systemic autoimmune diseases published in 2004
through 2009. We included studies that reported associations between laboratory markers and the presence of
disease, measures of disease activity, or prognosis. We examined the following design features: age, sex, and race
matching; control for effects of treatment on expression of the biomarker; inclusion of patients with both early and
late disease, or both active and inactive disease; longitudinal or cross-sectional design; and use of validated activity
and damage measures.
Results: Among 170 articles, 156 articles examined potential biomarkers for diagnosis, 37 for disease activity
assessment, and nine for prognosis; 67 were studies of rheumatoid arthritis (RA); 48, of systemic lupus
erythematosus; and 41, of other diseases. Gene-expression profiles were the most commonly examined potential
biomarkers (n = 51). Fewer than one half of studies incorporated study-design features important for valid clinical
associations. Only 47.4% of studies of biomarkers for diagnosis had groups that were age-matched, 45.5% were
sex-matched, and 35.3% controlled for treatment. Studies that examined biomarkers in histologic samples and
studies of RA were less likely to include important design features.
Conclusions: Fewer than one half of translational studies of potential biomarkers incorporated design features
needed for valid interpretation of clinical associations. Attention to these features could reduce false-positive and
false-negative associations.
Introduction
Dramatic recent progress in immunology has resulted in
the recognition of new pathways mediating inflammation
and tissue damage in systemic autoimmune diseases.
These discoveries have led to the identification of bio-
chemical, molecular, or genetic markers that indicate
normal and pathogenic biologic processes or pharmaco-
logic responses [1]. One goal of translational research is
to test whether these markers, characterized as biomar-
kers, have clinical application in improving diagnostic
accuracy or assessing disease activity, prognosis, and
treatment efficacy [2,3].
In early biomarker testing, the influence of confound-
ing factors and other sources of information bias should
be addressed [4-7]. Laboratory scientists are often the
first to examine clinical applications of their discoveries.
Laboratory scientists may not always design early transla-
tional studies with features that guard against confound-
ing and information bias but may rather test samples of
convenience. To know whether a biomarker is associated
with a disease, matching patients and healthy controls on
age and sex would be important.
Medications can also influence biomarker expression
and cause comparisons between patients and controls
to be spurious [8-10]. Biomarkers can be specific to
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any medium, provided the original work is properly cited.particular stages of disease (early or late) or particular
states of disease activity. False-positive or false-negative
associations may occur if studies include only certain
subsets of patients. It is not known how often these
issues, which can lead to misdirected efforts or prema-
ture abandonment of promising lines of research, are
considered in early studies of potential biomarkers.
The purpose of our study was to evaluate whether
recently published translational research studies that
examined biomarkers for diagnosis, disease activity, and
prognosis in systemic autoimmune diseases incorpo-
rated study-design features important for valid clinical
associations.
Materials and methods
Data sources and search
We systematically searched the last 5 years (May 2004
through June 2009) of nine basic research journals that
potentially included translational research articles on
new biomarkers for systemic autoimmune diseases: Jour-
nal of Immunology, J o u r n a lo fE x p e r i m e n t a lM e d i c i n e ,
Journal of Clinical Investigation, Nature, Nature Medi-
cine, Nature Immunology, Science, Proceedings of the
National Academy of Sciences of the USA,a n dImmu-
nity. We selected these journals because they may
include the initial studies of promising biomarkers.
Initial studies are informative because they are not influ-
enced by previous findings, but they may influence sub-
sequent development and testing of the biomarker. In
addition, among journals that focus on rheumatic dis-
eases, we included Arthritis and Rheumatism, the largest
rheumatology subspecialty journal, as a representative
clinical and basic-research journal. The journals and
number of years included were considered to provide a
broad survey of recent research.
We searched MEDLINE for the following systemic
autoimmune diseases: systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA), juvenile idiopathic
arthritis (or juvenile rheumatoid arthritis), Sjögren syn-
drome, anti-neutrophil cytoplasmic antibody-associated
vasculitis, and inflammatory myopathies. We included
several different diseases to increase the generalizability
of the results. We used as key words each disease name
in combination with the following terms for categories
of potential biomarkers: “cytokines,”“ cytokine recep-
tors,”“ chemokines,”“ chemokine receptors,”“ antibodies,”
“enzymes,”“ endothelial activation markers,”“ adhesion
molecules,”“ soluble cell-surface molecules,”“ cell surface
markers,”“ lymphocyte markers,”“ signaling molecules,”
“urinary markers,”“ gene expression,”“ transcriptomes,”
and “proteomes.” For example, we searched the key-
word combination “rheumatoid arthritis” and “gene
expression.” Separate searches were performed for each
combination of disease-name key word and biomarker-
category key word.
Study selection
We included studies that reported associations between
a laboratory marker (excluding imaging markers and
tests currently used in clinical practice) and either the
presence of disease, measures of disease activity, or
prognosis. We considered a study to be related to diag-
nosis if it reported the comparison of the potential bio-
marker between patients with autoimmune disease and
healthy controls. For studies examining potential bio-
markers for RA diagnosis, we also accepted studies that
used patients with osteoarthritis as the control group, as
this was a common practice among these studies. We
considered a study to be related to assessment of disease
activity if it reported comparisons of the potential bio-
marker between patients with active and inactive disease
or correlations with measures of disease activity. We
considered a study to be related to prognosis if it
reported associations with organ damage or mortality.
We excluded studies for the following reasons:
1. studies that did not include data on humans (that
is, exclusively animal models);
2. studies of genetic polymorphisms, because these
studies examine likelihood of disease susceptibility
rather than diagnosis;
3. studies of pathogenetic mechanisms and pathways,
rather than of specific molecules that could be used as
potential biomarkers;
4. studies of treatments or adverse events;
5. studies of other diseases or with a different purpose;
and
6. case reports, review articles, or commentaries.
We first screened titles and abstracts of the studies
and excluded clearly irrelevant studies. The full text of
all remaining studies was read.
Data extraction
Both authors read each article and abstracted data inde-
pendently by using a standard data-collection form. Dif-
ferences were reconciled by discussion. For each study,
we recorded the journal, disease examined, number of
patients, whether the study included data only on
humans or on both humans and animals, category of
potential biomarker, and type of specimen (for example,
serum, synovial fluid, histologic sample).
We collected data on study-design features important
for valid interpretation of clinical associations. These
features differed slightly for studies of diagnosis, disease
activity, or prognosis assessments (Table 1). If informa-
tion on a particular feature was not reported, it was
considered not to be present.
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We examined nine study-design features for studies that
compared patients with unaffected controls. We recorded
whether the disease and control groups were individually
matched or group matched for age, sex, and race, as
these may be important confounding factors. We consid-
ered groups to be matched for age if the samples were
reported as such by the authors, if the mean or median
ages in the disease and control groups were comparable
(within 8 years for studies of adults), or if, in the absence
of data on mean or median ages, the age ranges of the
groups substantially overlapped. We considered studies
to be matched for sex and race if they were reported as
such or if the proportions in disease and control groups
were within 15%. All studies fr o mA s i aw e r ec o n s i d e r e d
to be race matched. Methods to adjust for demographic
differences other than matching were not used in studies
of diagnosis.
Because medications can influence biomarker expres-
sion and would likely differ between disease and control
groups, we recorded whether information on medica-
tions was provided. Additionally, we evaluated whether
the authors reported any one of three possible methods
to control for confounding by treatment: enrollment of
treatment-naïve patients; testing whether biomarker
expression differed between groups of patients taking
different medications; or providing a reference from the
literature regarding associations between the potential
biomarker and any medication.
In addition, we recorded whether the study enrolled
patients who met accepted classification criteria, to
ensure that homogenous groups of patients were stu-
died. We also recorded whether both patients with
active disease and patients with inactive disease were
enrolled. Inclusion of both groups helps to avoid spec-
trum bias by ensuring that the biomarker is associated
with the disease itself, and not only with a particular
level of disease activity [11]. If only patients with active
disease were included, it would not be possible to know
whether the biomarker was a marker of the diagnosis or
a measure of disease activity. Similarly, we recorded
whether both patients with early disease and patients
with late disease were included, to determine whether
the biomarker was associated with the disease, regard-
less of stage. We noted whether any disease control
group was used to assess the specificity of associations
with the biomarker.
Studies of biomarkers for disease activity assessment
We examined eight study-design features (Table 1),
including whether patients with active and inactive dis-
ease were matched for age, sex, and race, or whether a
statistical adjustment was made for these factors, and
whether the authors reported any one of three possible
methods to control for confounding by treatment. We
recorded whether changes in the biomarker were
assessed longitudinally in some patients. Longitudinal
studies provide necessary information on the stability
and change of measures with disease activity. We also
recorded whether validated activity measures were used,
and whether patients with a wide range of disease activ-
ity were studied, which would help ensure that tests of
associations were adequate.
Studies of biomarkers of prognosis assessment
We examined seven design features (Table 1), including
age, sex, race matching (or statistical adjustment for
these factors), and testing of treatment differences
between patients with good or poor prognosis. The use
of validated measures of organ damage and longitudinal
or cross-sectional design also were evaluated.
Statistical analysis
We tabulated the proportion of studies that included
information on each study-design feature. Proportions
were reported separately for studies addressing diagno-
sis, disease-activity assessment, and prognosis, and for
each disease category.
For studies that assessed biomarkers for diagnosis, we
examined whether certain study characteristics were
Table 1 Study-design features evaluated in studies examining potential biomarkers
Diagnosis Disease activity Prognosis
Matched for age Matched for age Matched for age
Matched for sex Matched for sex Matched for sex
Matched for race Matched for race Matched for race
Provided information on medications Provided information on medications Provided information on medications
Controlled for treatment effects Controlled for treatment effects Controlled for treatment effects
Reported use of accepted classification criteria Reported use of validated disease-activity
measures
Reported use of validated measures of
damage
Included patients with both early and late disease Longitudinal versus cross-sectional design Longitudinal versus cross-sectional design
Included patients with both active and inactive
disease
Included a wide range of disease-activity scores
Included disease controls
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more likely to have been included. These characteristics
were disease (RA versus other); number of patients;
studies with data on humans and animals versus studies
that included only data on humans; category of biomar-
ker; measurement of the biomarker on histologic speci-
mens versus other types of specimens; and journal. We
first examined these associations in univariate analyses
by using c
2 tests. Next we used these characteristics as
the independent variables in multivariate logistic regres-
sion models that predicted the presence or absence of
the study-design features. Each study-design feature was
used as the dependent variable in separate models.
These models provided adjusted odds ratios that esti-
mated whether, for example, studies that included larger
numbers of patients were more or less likely to include
age-matched samples, adjusting for disease, inclusion of
animal data, category of biomarker, examination of his-
tologic specimens, and journal. We considered 95% con-
fidence intervals of the odds ratio that did not include
1.0 to be statistically significant. The adequacy of model
fit was assessed by using the Hosmer-Lemeshow test.
Too few studies of disease-activity assessment and prog-
nosis assessment were available to permit a similar ana-
lysis. We used SAS programs version 9.2 (SAS Institute,
Cary, NC) for all analyses.
Results
Results of the literature search
We identified 1,341 unique articles. Of these, we
excluded 1,171 articles (Figure 1). Among the 170 arti-
cles included, 156 articles examined potential biomar-
kers for diagnosis, 37 articles examined disease activity
assessment, and nine articles examined prognosis (arti-
cles are listed in the Appendix in Additional file 1).
Twenty articles evaluated potential biomarkers for both
diagnosis and disease-activity assessment, four for both
diagnosis and prognosis, and three for both disease
activity and prognosis. Most articles (n = 119) were pub-
lished in Arthritis and Rheumatism,3 9i nJournal of
Immunology,f i v ei nJournal of Experimental Medicine,
and seven in the remaining journals. Thirteen studies
included data on both humans and animals. The cate-
gories of potential biomarkers are shown in Table 2.
Studies of biomarkers for diagnosis
The median number of patients in these studies was 22
(range, 3 to 204), and the median number of controls
w a s1 5( r a n g e ,1t o2 6 0 ) .G e n e - e x p r e s s i o np r o f i l ew a s
the most frequent category of biomarker, followed by
cytokines or cytokine receptors or both, cell-surface
markers, and lymphocyte markers. In 36% of studies,
the biomarker measurements were based on histologic
specimens.
Fewer than one-half of studies included groups that
were age and sex matched to controls, provided informa-
tion on medications, or included both patients with active
disease and patients with inactive disease (Table 3). For
example, 47.4% of studies had age-matched groups, and
46.1% had sex-matched groups. Moreover, 44 (28.2%) stu-
dies did not report any information on age, 47 (30.1%) stu-
dies did not report sex, and 102 (65.4%) studies did not
report race. Only 35.3% of studies reported any of the
three approaches to control for treatment differences.
Fewer studies in RA included these design features than
did studies in SLE or other diseases, and 22.4% of RA stu-
dies did not report whether patients met accepted classifi-
cation criteria.
Three (1.9%) studies included all nine study-design
features, 61.2% of studies included at least four features,
but only 18% of studies simultaneously controlled for
age, sex, and treatment differences. An example of a
study that included all nine design features was the
2006 report by Feng and colleagues [12] of the associa-
tion between interferon-inducible gene expression and
SLE. Expression of a set of five interferon-inducible
genes was found to be increased among 48 patients with
SLE compared with 48 healthy controls and 22 disease
controls matched for age, sex, and ethnicity. The
patients with SLE fulfilled current classification criteria,
had durations of SLE that ranged from less than 1 year
to 37 years, and had scores for SLE activity that ranged
from inactive to very active. Interferon scores were not
associated with the type or intensity of immunosuppres-
sive treatment, after accounting for SLE activity.
We examined whether selected study characteristics
were associated with the likelihood that important
study-design features had been reported. In univariate
analyses, studies with smaller numbers of subjects, stu-
dies of RA, and studies that examined histologic speci-
mens were less likely to include these study-design
features. Studies using histologic specimens were smaller
(median number of patients, 10) than other studies
(median number, 36), and most often examined RA
(55.3%). To distinguish which of these factors were inde-
pendently associated with the likelihood that each study-
design feature had been included, we used multivariate
logistic regression analysis. In these analyses, studies
that measured biomarkers on histologic specimens were
significantly less likely to include age-matched groups,
report the medications used by patients, control for
treatment differences, include patients with both early
and late disease, and include patients with both active
and inactive disease (Figure 2). Studies of RA were
significantly less likely than studies of other diseases to
control for treatment effects, report using accepted clas-
sification criteria, and include patients with both active
and inactive disease (Figure 3). Larger studies were
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odds ratio (aOR) (per each additional 10 patients), 1.16;
95% confidence interval (CI), 1.03 to 1.30), race-matched
groups (aOR, 1.18; 95% CI, 1.03 to 1.36), and patients
with both active and inactive disease (aOR, 1.30; 95%
CI, 1.08 to 1.57).
Biomarkers for disease-activity assessment
The median number of patients was 45 (range, 9 to
245). Only one third of studies adjusted for group differ-
ences in age and sex; 56.8% reported at least one
method to control for treatment effects; and 45.9% had
a longitudinal component (Table 4). Studies in RA were
less likely to report adjustment for age and sex and to
control for treatment effects, than were studies in SLE.
No studies that examined histologic specimens reported
that groups were adjusted for age, sex, or race, whereas
31.4%, 34%, and 45.7%, respectively, of studies that
examined other types of specimens did so.
Biomarkers for prognosis assessment
The median number of patients was 60 (range, 15 to
92). Few studies adjusted for group differences in age
(44.4%) or sex (22.2%), or had a longitudinal component
(33.3%). Two thirds of studies controlled for treatment
effects, and all reported using validated outcome
measures.
Discussion
The diagnosis, monitoring, and management of patients
with systemic autoimmune diseases remain challenging,
prompting a continuing search for better biomarkers. In
the progression from exploratory to validated status,
biomarkers must undergo careful evaluation of sources
of variation [5-7,13-15]. We found that fewer than one
half of translational studies of biomarkers included
study-design features needed for valid interpretation of
clinical associations.
Gene-expression profiles were the most common poten-
tial biomarkers. If the patient and control groups are not
comparable in biologic factors that might influence gene
expression, the association of a particular set of genes with
disease may be mistaken, whereas an unrecognized set of
genes may be the true disease-associated set. Two large-
scale surveys of variation in gene expression in healthy
subjects showed substantial differences within individuals
Figure 1 Results of the literature search and selection.
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Immune-related genes, including those for immunoglobu-
lins and genes that are regulated by interferons, were
among the genes most often found to be differentially
expressed by age and sex [16,17]. This is particularly rele-
vant because patterns of expression of specific type 1
interferon-regulated genes, so-called “interferon signa-
tures,” have been proposed as useful biomarkers in SLE
and inflammatory myopathies [18,19]. Moreover, if gene
expression is differentially regulated by medications, misi-
dentification of treatment-responsive genes as disease-
related signatures may occur. Similar effects can occur for
other categories of biomarkers.
Studies of biomarkers of disease activity have an
additional limitation if they are examined only cross-
sectionally. Cross-sectional studies compare expression
of the biomarker between patients with active and
inactive disease, without evidence that expression can
change as disease activity changes. Longitudinal studies
of patients who experience changes in activity provide
a more valid design [5,6]. Fewer than one half of stu-
dies included a longitudinal design.
Table 2 Categories of potential biomarkers examined in translational studies of systemic autoimmune diseases
Biomarkers for diagnosis
All diseases SLE RA Other diseases
a
n = 156 n =4 8 n =6 7 n =4 1
Categories of biomarkers n (%) n (%) n (%) n (%)
Gene expression 48 (30.8) 9 (18.7) 26 (38.8) 13 (31.7)
Cytokines and receptors 26 (16.7) 6 (12.5) 10 (14.9) 10 (24.4)
Cell-surface markers 23 (14.7) 8 (16.7) 11 (16.4) 4 (9.8)
Lymphocyte markers 20 (12.8) 14 (29.2) 2 (3.0) 4 (9.8)
Chemokines and receptors 11 (7.0) 2 (4.2) 4 (6.0) 5 (12.2)
Miscellaneous
b 8 (5.1) 1 (2.1) 4 (6.0) 3 (7.3)
Enzymes 6 (3.8) 2 (4.2) 3 (4.5) 1 (2.4)
Endothelial activation markers 5 (3.2) 2 (4.2) 3 (4.5) 0
Soluble cell-surface molecules 4 (2.5) 1 (2.1) 2 (3.0) 1 (2.4)
Signaling molecules 3 (1.9) 2 (4.2) 1 (1.5) 0
Proteomes 2 (1.3) 1 (2.1) 1 (1.4) 0
Biomarkers for disease activity
All diseases SLE RA Other diseases
a
n =3 7 n =2 7 n =9 n =1
n (%) n (%) n (%) n (%)
Gene expression 10 (27.0) 7 (25.9) 2 (22.2) 1 (100.0)
Lymphocyte markers 8 (21.6) 7 (25.9) 0 0
Cell-surface markers 8 (21.6) 8 (29.6) 1 (11.1) 0
Cytokines and receptors 4 (10.8) 1 (3.7) 3 (33.3) 0
Chemokines and receptors 4 (10.8) 1 (3.7) 3 (33.3) 0
Soluble cell-surface molecules 2 (5.4) 2 (7.4) 0 0
Proteomes 1 (2.7) 1 (3.7) 0 0
Biomarkers for prognosis
All diseases SLE RA Other diseases
a
n =9 n =3 n =5 n =1
n (%) n (%) n (%) n (%)
Cytokines and receptors 2 (22.2) 0 2 (50.0) 0
Chemokines and receptors 2 (22.2) 1 (33.3) 0 1 (100.0)
Gene expression 2 (22.2) 1 (33.3) 1 (25.0) 0
Miscellaneous
b 2 (22.2) 1 (33.3) 1 (25.0)
Proteomes 1 (11.1) 0 1 (25.0) 0
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
aJuvenile idiopathic arthritis, Sjögren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, and inflammatory myopathies.
bMiscellaneous: uncommonly studied biomarkers such as antibodies, enzymes, and urinary markers.
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positively associated with the disease investigated,
despite often-limited attention to confounding. Of
greater concern is the possibility that other studies failed
to detect associations because of inattention to these
issues. The failure to consider matching, treatment
effects, and other study-design features might have led
investigators to conclude that no association was pre-
sent, and therefore, to abandon potentially promising
biomarkers. False-negative results may be common, but
because negative studies may not be reported, the extent
of this problem is difficult to assess.
Studies based on histologic specimens and studies of
RA were less likely to address important study-design
features than were studies based on serum or other
sources and studies of SLE or other diseases, respec-
tively. Although studies of histologic specimens were
generally of smaller size, and most often were studies of
Table 3 Proportion of studies examining potential biomarkers for diagnosis that incorporated important study-design
features
All diseases SLE RA Other diseases
a
n = 156 n =4 8 n =6 7 n =4 1
Study-design features n (%) n (%) n (%) n (%)
Matched for age 74 (47.4) 30 (62.5) 23 (34.3) 21 (51.2)
Matched for sex 72 (46.1) 28 (58.3) 24 (35.8) 20 (48.8)
Matched for race 51 (32.7) 23 (47.9) 20 (29.8) 8 (19.5)
Provided information on medications 79 (50.6) 34 (70.8) 25 (37.3) 20 (48.8)
Controlled for treatment effects 55 (35.3) 25 (52.0) 13 (19.4) 17 (41.4)
Reported use of accepted classification criteria 140 (89.7) 48 (100.0) 52 (77.6) 40 (97.6)
Included patients with both early and late disease 43 (27.6) 16 (33.0) 18 (26.9) 9 (21.9)
Included patients with both active and inactive disease 58 (43.3) 40 (83.3) 15 (22.4) 3 (15.8)
Included disease controls 61 (39.1) 27 (56.2) 16 (23.9) 18 (43.9)
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
aJuvenile idiopathic arthritis, Sjögren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, and inflammatory myopathies.
Figure 2 Associations between studies using histologic specimens (versus other types of specimens) and the presence of each study-
design feature, by multivariate logistic regression analysis. Odds ratios <1.0 indicate that the study-design feature was less common in
studies using histologic specimens, whereas odds ratios >1.0 indicate that the study-design feature was more common in studies of histologic
specimens. Error bars are 95% confidence limits. Odds ratios were based on models that also included disease (RA versus other), journal, the
number of patients, data on animals, and category of biomarker as independent variables. Separate models were estimated for each study-
design feature. Each model fit the data well (all Hosmer-Lemeshow test, P > 0.09).
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of both sample size and disease. Attention to study-
design features may be less prevalent among these
studies because histologic samples are more difficult to
obtain, and specimens are used when they become avail-
able. In studies of animal models, age, sex, and genetic
background are considered important factors to be con-
trolled. Human studies should similarly consider these
factors. Larger studies, likely representing biomarkers at
am o r ea d v a n c e ds t a g eo fe v a l u a t i o n ,m o r eo f t e n
reported important study-design features.
Our results reflect existing community standards for
studies in systemic autoimmune diseases. The deficien-
cies may be due in part to incomplete reporting rather
than to omissions in the study design. Adoption of uni-
form reporting criteria would be one remedy for this
problem. To the extent that these deficiencies are due
to omissions in study design, our results raise questions
Figure 3 Associations between studies of RA (versus SLE and other diseases) and the presence of each study-design feature, by
multivariate logistic regression analysis. Odds ratios <1.0 indicate that the study-design feature was less common in studies of RA, whereas
odds ratios >1.0 indicate that the study-design feature was more common in studies of RA. Error bars are 95% confidence limits Odds ratios
were based on models that also included the type of specimen, journal, the number of patients, data on animals, and category of biomarker as
independent variables. Separate models were estimated for each study-design feature. Each model fit the data well (all Hosmer-Lemeshow test,
P > 0.09).
Table 4 Proportion of studies examining potential biomarkers for disease activity that incorporated important study-
design features
All diseases SLE RA Other diseases
a
n =3 7 n =2 7 n =9 n =1
Study-design features n (%) n (%) n (%) n (%)
Adjusted for age 11 (29.7) 10 (37.0) 1 (11.1) 0
Adjusted for sex 12 (32.4) 11 (40.7) 1 (11.1) 0
Adjusted for race 16 (43.2) 11 (40.7) 4 (44.4) 1 (100.0)
Provided information on medications 23 (62.1) 18 (66.7) 4 (44.4) 1 (100.0)
Controlled for treatment effects 21 (56.8) 16 (59.2) 4 (44.4) 0
Longitudinal component 17 (45.9) 11 (40.7) 5 (55.6) 1 (100.0)
Validated disease-activity measures 34 (91.9) 27 (100.0) 7 (77.8) 0
Included wide range of disease activity 34 (91.9) 24 (88.9) 9 (100.0) 1 (100.0)
RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.
aJuvenile idiopathic arthritis, Sjögren syndrome, anti-neutrophil cytoplasmic antibody-associated vasculitis, and inflammatory myopathies.
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applications of the biomarker is often overshadowed by
the novelty of the laboratory science.
The strengths of this study include examination of a
diverse set of potential biomarkers in several diseases,
many study-design features, and three clinical applica-
tions. However, our conclusions about biomarkers for
prognosis are limited by the small number of studies.
Inclusion of additional years or journals might have
increased the number of studies, but our search pro-
vided a broad representation of recent studies. Some
study-design features, such as adjustment for age, sex,
and treatment effects, may be considered more impor-
tant than others, but we examined a broader set of
features without suggesting a hierarchy among them.
The proportion of studies that included age, sex, or
race adjustment was low, even though our criteria for
matching were liberal. Although we examined only sys-
temic autoimmune diseases, similar results may occur
in other diseases such as osteoarthritis, spondyloarthri-
tis, cancer, or cardiovascular disease [20-25].
Conclusions
Many early studies of potential biomarkers in systemic
autoimmune diseases did not include design features
important for valid clinical associations. Greater atten-
tion to the design of translational studies of biomarkers
would result in more-accurate assessments of their
potential clinical applications and reduce false-positive
and false-negative associations. Researchers should
include adjustment for differences in demographic char-
acteristics and test whether commonly used treatments
affect the biomarker. Studies of biomarkers of disease
activity should include a longitudinal component. Read-
ers of studies of new biomarkers should assess whether
these study-design features were included. Biomarker
discovery may benefit from greater involvement by clini-
cal epidemiologists in the design of early translational
studies.
Additional material
Additional file 1: Appendix. Reference list of articles included in the
study.
Abbreviations
aOR: adjusted odds ratio; RA: rheumatoid arthritis; SLE: systemic lupus
erythematosus.
Acknowledgements
This work was supported by the Intramural Research Program, National
Institute of Arthritis and Musculoskeletal and Skin Diseases, National
Institutes of Health.
Author details
1Intramural Research Program, National Institute of Arthritis and
Musculoskeletal and Skin Diseases, National Institutes of Health, 10 Center
Drive, Bethesda, MD 20892, USA.
2Euroclinic Hospital, 9 Athanassiadou Street,
11521 Athens, and First Department of Internal Medicine, School of
Medicine, National University of Athens, 75 M Asias Street, 11527 Athens,
Greece.
Authors’ contributions
MGT and MMW designed the study. MGT performed the literature search.
MGT and MMW abstracted the data. MMW performed the statistical analysis.
MGT drafted the manuscript. MMW participated in revising the draft. Both
authors approved the final version.
Competing interests
The authors declare that they have no competing interests.
Received: 28 May 2010 Revised: 24 August 2010
Accepted: 27 September 2010 Published: 27 September 2010
References
1. Biomarkers Definition Working Group: Biomarkers and surrogate
endpoints: preferred definitions and conceptual framework. Clin
Pharmacol Ther 2001, 69:89-95.
2. Paul M: Translational investigators: life sciences’ application engineers.
Nat Biotechnol 2007, 25:817-818.
3. Ozdemir V, Williams-Jones B, Cooper DM, Someya T, Godard B: Mapping
translational research in personalized therapeutics: from molecular
markers to health policy. Pharmacogenomics 2007, 8:177-185.
4. Muñoz A, Gange SJ: Methodological issues for biomarkers and
intermediate outcomes in cohort studies. Epidemiol Rev 1998, 20:29-42.
5. Ward MM: Evaluative laboratory testing: assessing tests that assess
disease activity. Arthritis Rheum 1995, 38:1555-1563.
6. Illei GG, Tackey E, Lapteva L, Lipsky PE: Biomarkers in systemic lupus
erythematosus, I: general overview of biomarkers and their applicability.
Arthritis Rheum 2004, 50:1709-1720.
7. Illei GG, Tackey E, Lapteva L, Lipsky PE: Biomarkers in systemic lupus
erythematosus, II: markers of disease activity. Arthritis Rheum 2004,
50:2048-2065.
8. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V:
Interferon and granulopoiesis signatures in systemic lupus
erythematosus blood. J Exp Med 2003, 197:711-723.
9. Kehlen A, Thiele K, Riemann D, Langner J: Expression, modulation and
signalling of IL-17 receptor in fibroblast-like synoviocytes of patients
with rheumatoid arthritis. Clin Exp Immunol 2002, 127:539-546.
10. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG, Szapary P,
Wilensky R, Rader DJ, Lazar MA, Reilly MP: CXCL16 is a marker of
inflammation, atherosclerosis, and acute coronary syndromes in
humans. J Am Coll Cardiol 2007, 49:442-449.
11. Ransohoff DF, Feinstein AR: Problems of spectrum and bias in evaluating
the efficacy of diagnostic tests. N Engl J Med 1978, 299:926-930.
12. Feng X, Wu H, Grossman J, Hanvivadhanakul P, FitzGerald JD, Park GS,
Dong X, Chen W, Kim MH, Weng HH, Furst DE, Gorn A, McMahon M,
Taylor M, Brahn E, Hahn BH, Tsao BP: Association of increased interferon-
inducible gene expression with disease activity and lupus nephritis in
patients with systemic lupus erythematosus. Arthritis Rheum 2006,
54:2951-2962.
13. Liang MH, Simard JF, Costenbader K, Dore BT, Ward M, Fortin PR, Illei GG,
Manzi S, Mittleman B, Buyon J, Gupta S, Abrahamowicz M: Methodologic
issues in the validation of putative biomarkers and surrogate end points
in treatment evaluation for systemic lupus erythematosus. Endocr Metab
Immune Disord Drug Targets 2009, 9:108-112.
14. Liu CC, Ahearn JM: The search for lupus biomarkers. Best Pract Res Clin
Rheumatol 2009, 23:507-523.
15. Smolen JS, Aletaha D, Grisar J, Redlich K, Steiner G, Wagner O: The need
for prognosticators in rheumatoid arthritis: biological and clinical
markers: where are we now? Arthritis Res Ther 2008, 10:208.
Tektonidou and Ward Arthritis Research & Therapy 2010, 12:R179
http://arthritis-research.com/content/12/5/R179
Page 9 of 1016. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA,
Brown PO: Individuality and variation in gene expression patterns in
human blood. Proc Natl Acad Sci USA 2003, 100:1896-1901.
17. Eady JJ, Wortley GM, Wormstone YM, Hughes JC, Astley SB, Foxall RJ,
Doleman JF, Elliott RM: Variation in gene expression profiles of peripheral
blood mononuclear cells from healthy volunteers. Physiol Genomics 2005,
22:402-411.
18. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK: Activation of
the interferon-alpha pathway identifies a subgroup of systemic lupus
erythematosus patients with distinct serological features and active
disease. Arthritis Rheum 2005, 52:1491-1503.
19. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J,
Ytterberg SR, Gregersen PK, Behrens TW, Reed AM: An interferon signature
in the peripheral blood of dermatomyositis patients is associated with
disease activity. Mol Med 2007, 13:59-68.
20. Sawyers CL: The cancer biomarker problem. Nature 2008, 452:548-552.
21. Simon R: Lost in translation: problems and pitfalls in translating
laboratory observations to clinical utility. Eur J Cancer 2008, 44:2707-2713.
22. Chau CH, Rixe O, McLeod H, Figg WD: Validation of analytic methods for
biomarkers used in drug development. Clin Cancer Res 2008,
14:5967-5976.
23. Floyd E, McShane TM: Development and use of biomarkers in oncology
drug development. Toxicol Pathol 2004, 32(suppl 1):106-115.
24. Clerico A, Vittorini S, Passino C, Emdin M: New and emerging biomarkers
of heart failure. Crit Rev Clin Lab Sci 2009, 46:107-128.
25. Andreassi MG, Gastaldelli A, Clerico A, Salvadori PA, Sicari R, Picano E:
Imaging and laboratory biomarkers in cardiovascular disease. Curr Pharm
Des 2009, 15:1131-1141.
doi:10.1186/ar3143
Cite this article as: Tektonidou and Ward: Validity of clinical associations
of biomarkers in translational research studies: the case of systemic
autoimmune diseases. Arthritis Research & Therapy 2010 12:R179.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tektonidou and Ward Arthritis Research & Therapy 2010, 12:R179
http://arthritis-research.com/content/12/5/R179
Page 10 of 10